Floatz Rating
BB71/100
Confidence
Indicative
Sponsor
Seoul National University Hospital
Modality
Small molecule
Development Phase
Phase 4 / Approved
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
64High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT02283294CT.gov Apixaban for Early Prevention of Recurrent Embolic Stroke and Hemorrhagic Transformation | — | Completed | — | — | — |
NCT02042534CT.gov Rivaroxaban Versus Warfarin in Acute Ischemic Stroke With Atrial Fibrillation | — | Completed | — | — | — |
NCT00235248CT.gov Aortic Arch Related Cerebral Hazard Trial (ARCH) | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
81High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Transient Ischemic Attack
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Warfarin (this asset) | Seoul National University Hospital | Approved | BB · 71 |
| Aspirin | Sichuan Provincial People's Hospital | P4 | BBB |
| Clopidogrel | Sichuan Provincial People's Hospital | P4 | BBB |
| Cilostazol | Stanford University | P4 | BBB |
| Ticagrelor | Mazandaran University of Medical Sciences | P3 | BBB |
| Apixaban | Centre de Recherche de l'Institut Universitaire de Cardiologie et de Pneumologie de Quebec | P4 | BBB |
| Rivaroxaban | General Hospital of Shenyang Military Region | P4 | BBB |
| 3-N-BUTYLPHTHALIDE | Peking Union Medical College Hospital | P4 | BBB |
| Nxy-059 | AstraZeneca | P3 | BB |
+34 more in the Transient Ischemic Attack cohort
Other indications for Warfarin
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Venous Thromboembolism | — | P4 | A · 81 |
| Atrial Fibrillation | — | P4 | BBB · 77 |
| Hemorrhagic Disease | — | P4 | BBB · 74 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Warfarin in Transient Ischemic Attack. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/warfarin-transient-ischemic-attack
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →